Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRLD 
Prelude Therapeutics Inc (PRLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PRLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.61% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.66M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 0.61 - 2.72 | Updated Date 09/17/2025 |
52 Weeks Range 0.61 - 2.72 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1928.67% |
Management Effectiveness
Return on Assets (TTM) -49.75% | Return on Equity (TTM) -96.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7527382 | Price to Sales(TTM) 9.38 |
Enterprise Value 7527382 | Price to Sales(TTM) 9.38 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA -0.54 | Shares Outstanding 43750100 | Shares Floating 29179176 |
Shares Outstanding 43750100 | Shares Floating 29179176 | ||
Percent Insiders 11.34 | Percent Institutions 62.34 |
Upturn AI SWOT
Prelude Therapeutics Inc
Company Overview
History and Background
Prelude Therapeutics Incorporated, founded in 2016, is a clinical-stage biopharmaceutical company focused on developing small molecule therapies targeting protein kinases and other cancer drug targets. The company aims to develop differentiated therapies for patients with cancer.
Core Business Areas
- PRMT5 Inhibitors: Focuses on developing inhibitors of protein arginine methyltransferase 5 (PRMT5), a key enzyme in cancer cell growth and survival.
- SMO Inhibitors: Developing inhibitors of Smoothened (SMO), a protein involved in the Hedgehog signaling pathway, which is often dysregulated in certain cancers.
Leadership and Structure
Prelude Therapeutics is led by Dr. Krishna Vaddi, Ph.D., as CEO. The company has a management team with expertise in drug discovery, clinical development, and commercialization. It operates with a functional organizational structure focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- PRT543 (PRMT5 Inhibitor): PRT543 is Prelude's lead drug candidate, an oral, selective PRMT5 inhibitor being evaluated in clinical trials for various solid tumors and hematological malignancies. Market share data not publicly available yet as it is still in clinical stage. Competitors include companies developing other PRMT5 inhibitors and therapies for the same cancer types.
- PRT811 (SMO Inhibitor): PRT811 is an oral SMO inhibitor being developed for cancers driven by aberrant Hedgehog pathway signaling. Market share data not publicly available yet as it is still in clinical stage. Competitors include companies developing other SMO inhibitors and therapies for the same cancer types such as basal cell carcinoma.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It involves the discovery, development, manufacturing, and commercialization of pharmaceutical products for the treatment of various diseases. The oncology market is a major segment within this industry, driven by the high prevalence and unmet needs in cancer treatment.
Positioning
Prelude Therapeutics is positioned as a clinical-stage company focused on developing novel small molecule therapies for cancer. Its competitive advantage lies in its expertise in targeting specific protein kinases and other cancer drug targets with differentiated therapeutic potential.
Total Addressable Market (TAM)
The global oncology market is projected to reach billions of dollars. Prelude Therapeutics targets specific segments within the oncology market based on the mechanisms of action of its drug candidates. Their positioning is dependent on successful clinical trials and regulatory approvals, but if successful they could capture a significant portion of the TAM.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting validated cancer pathways
- Experienced management team
- Strong intellectual property portfolio
- Clinical-stage pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- Dependence on key personnel
Opportunities
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Positive clinical trial results leading to regulatory approvals
- Growing demand for targeted cancer therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRTX
- GILD
- TAK
Competitive Landscape
Prelude faces competition from larger pharmaceutical companies with greater resources and established market presence. Its success depends on demonstrating the efficacy and safety of its drug candidates in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is measured by pipeline advancement and funding milestones.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential commercialization of its drug candidates. Analyst estimates vary based on clinical trial data.
Recent Initiatives: Recent initiatives include advancing PRT543 and PRT811 through clinical trials, presenting clinical data at scientific conferences, and securing additional funding.
Summary
Prelude Therapeutics is a clinical-stage biopharmaceutical company with promising cancer therapies in development, particularly PRT543. While the company is well-positioned in terms of drug development and scientific expertise, it faces challenges related to financial resources and the inherent risks of clinical trials. Success hinges on positive trial outcomes and securing partnerships. The company needs to maintain a focus on intellectual property protection and adapting to evolving regulatory landscapes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Prelude Therapeutics Investor Relations
- SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source and definition. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Ratings and analysis based on available information and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prelude Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2020-09-25 | Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://preludetx.com |
Full time employees 131 | Website https://preludetx.com | ||
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.